OCC Trading, page-1675

Can't help wondering if something soon to be announced in Cynata (IPSC - phase 1 thought to phase 3 in a few applications) that might affect the stem cell realm in Australia. Just been steady progressive buying (admittedly in light volumes) with price not really being an issue.:




It's funny. Whilst we had a few big shot investors in OCC from WA, a guy who used to live a few of doors up (I in a far more modest unit don't worry) from me just dropped $50mill on a dubious Panama Mesenchymal Stromal venture (reported in the AFR):

https://www.copyright link/rich-list/behind-ian-malouf-s-50m-bet-on-umbilical-cords-20240520-p5jf4k

Will get in his ear if I see him down the pub as an OCC recipient and patient! He is probably entirely ignorant of it's decade of tenocyte/chondrocyte stem-cell treatments in Australia like most investors. At these lowly prices and mkt caps, one decent investment can change the fortunes of companies that should be trading far higher on the merit of their clinical trials and approved products.

Whilst OCC is shopping ATI in the US, there is plenty of money in Australia looking for investment if you know where to look. I do hope OCC don't spin off ATI for cash and actually insist on some form of a commercial partnership.